Next Article in Journal
The Antimicrobial Resistance (AMR) Rates of Uropathogens in a Rural Western African Area—A Retrospective Single-Center Study from Kpando, Ghana
Next Article in Special Issue
Antimicrobial Stewardship Program for Patients in the Hematological Department Receiving Carbapenem Therapy: A Single-Center and Interrupted Time Series Analysis
Previous Article in Journal
Predictors and Outcomes of Healthcare-Associated Infections among Patients with COVID-19 Admitted to Intensive Care Units in Punjab, Pakistan; Findings and Implications
Previous Article in Special Issue
Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 11
Issue 12
10.3390/antibiotics11121807
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association between Carbapenem Consumption and Clinical Outcomes in an In-Hospital Setting: Analysis of a Japanese Nationwide Administrative Database in 2020

by
Kozue Yamaguchi
1,
Masayuki Maeda
1,*,
Norio Ohmagari
2 and
Yuichi Muraki
3
1
Division of Infection Control Sciences, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo 142-8555, Japan
2
AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo 162-8655, Japan
3
Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan
*
Author to whom correspondence should be addressed.
Antibiotics 2022, 11(12), 1807; https://doi.org/10.3390/antibiotics11121807
Submission received: 4 November 2022 / Revised: 9 December 2022 / Accepted: 10 December 2022 / Published: 13 December 2022
(This article belongs to the Special Issue Antimicrobial Prescribing and Antimicrobial Use in Healthcare Settings)
Browse Figures
Review Reports Versions Notes

Abstract

:
This study aimed to clarify the relationship between carbapenem consumption and clinical outcome using the diagnosis procedure combination (DPC) payment system database (2020) published by the Ministry of Health, Labour, and Welfare of Japan. This study divided 5316 medical facilities subject to aggregation into five facilities and calculated the median values, including facility characteristics, clinical outcomes, and carbapenem consumption. Next, a correlation analysis was performed between carbapenem consumption and clinical outcome, as well as a multiple regression analysis between carbapenem consumption as the dependent variable and clinical outcome, bed size, and proportion of patients by disease as independent variables. Additionally, three clinical outcomes available from the DPC payment system database were selected, including cure, readmission within 4 weeks, and the average length of stay. This study revealed no relationship between carbapenem consumption and clinical outcome in university hospitals and university hospital-equivalent community hospitals; however, a relationship was suggested in the community, DPC-prepared, and non-DPC hospitals. University hospitals and university hospital-equivalent community hospitals with a high consumption of carbapenems may need to reconsider the classification because of the limited number of facilities in this classification.

1. Introduction

Carbapenems, which are broad-spectrum antibacterial agents, have a high degree of tissue penetration and antibacterial activity against most Gram-negative bacilli, including antimicrobial-resistant (AMR) Enterobacterales and glucose-nonfermenting bacteria [1]. Guidelines recommend carbapenems as the first-line drug for severe infections due to resistant bacteria such as extended-spectrum beta-lactamase (ESBL)-producing bacteria [2]. The overuse of carbapenems, which have high efficacy and safety, is a concern because it is selected as an empirical treatment before identifying the causative bacterium and infected organ [1]. Therefore, carbapenem-resistant Enterobacterales (CRE) has become a major problem worldwide [3,4]. Additionally, the number of CRE detection has increased in Japan over the years [5,6]. The Japanese government launched a National Action Plan for AMR, and efforts are made at each facility to reduce unnecessary antimicrobial consumption, including carbapenems [7].
Carbapenem consumption should be kept to a minimum to conserve carbapenem efficacy in the future [8,9,10,11]. In Japan, carbapenem consumption accounted for approximately 10% of all parenteral antimicrobial consumption [12]. A previous study revealed that most carbapenems consumption included meropenem and doripenem in Japan because ertapenem was not approved [13]. Terahara et al. revealed a positive correlation between carbapenem consumption and carbapenem-resistant P. aeruginosa isolation in Japan [14]. Therefore, an antibiotic restriction, which is one of the antimicrobial stewardship programs, has been recommended to reduce unnecessary antibiotic consumption [15]. The Japanese medical reimbursement system for antimicrobial stewardship required restriction of in-hospital broad-spectrum antibiotic consumption such as carbapenems [16]. An antibiotic registration or notification system was implemented in Japanese acute hospitals to restrict inappropriate carbapenem consumption by the antimicrobial stewardship team (AST) [17,18]. However, patients’ poor clinical outcomes due to excessive carbapenem restriction should be avoided.
The diagnosis procedure combination (DPC) payment system is a comprehensive assessment system based on diagnostic group classification for acute hospitalization [19,20]. DPC was developed as a measuring tool for transparent inpatient care to standardize Japanese medical care, as well as evaluate and improve its quality. Medical institution categories have been classified as the university hospital group, university-equivalent community hospital group, and community hospital group. Over 60% of hospitals in Japan submit “DPC data” to the Ministry of Health, Labor, and Welfare (MHLW). DPC data include the discharge abstract and administrative claims data of inpatients. The MHLW collects the data for the purpose of health policy planning, including the DPC-based reimbursement system. The MHLW disclosed DPC data, including carbapenem-defined daily dose (DDD) in each hospital [21]. These data are suitable for analysis of the association between carbapenem consumption and various medical data in hospital settings. However, existing antibiotic consumption metrics, including DDD, and days of therapy do not reflect both antimicrobial appropriateness and indications [22,23]. Monitoring of conventional antimicrobial metrics alone is insufficient to evaluate patient outcomes [23,24,25]. Specific data on an association between carbapenem consumption and the patient’s clinical outcomes remains lacking [17,18]. Thus, the present study aimed to reveal the association between hospital carbapenem consumption and clinical outcomes, including discharge, readmission, and length of stay using a national database.

2. Results

2.1. Characteristics of Hospitals Stratified by Classification of Payment System

This study analyzed the DPC payment database on carbapenem consumption (presented as DDDs per 1000 patient days) that comprise 5316 healthcare facilities collected by the MHLW in the fiscal year 2020. This study included 82 university hospitals, 156 university hospital-equivalent community hospitals, 1510 community hospitals, 242 DPC-prepared hospitals, and 2918 non-DPC (fee-for-service payment) hospitals after excluding 408 facilities with missing data (Figure 1). Table 1 shows the characteristics and clinical outcomes of each facility stratified by facility type. University hospitals and university hospital-equivalent community hospitals consisted of large-sized hospitals, and community and non-DPC hospitals consisted of small to medium hospitals.
Figure 2 shows the carbapenem consumption stratified by facility type. As a result of the Kruskal-Wallis test, significant differences in carbapenem consumption were observed among the five groups (p < 0.001). There was no significant difference only between the university hospitals and the university-equivalent community hospitals. The median DDDs/1000 patient days in university hospitals were higher compared with community hospitals and non-DPC hospitals. Carbapenem consumption in community hospitals and non-DPC hospitals had a large dispersion.

2.2. Correlation Analysis between Carbapenem Consumption and Clinical Outcomes Stratified by Facility Type

Table 2 shows the correlation analysis between carbapenem consumption and clinical outcome for each facility type. No strong correlation was found between DDDs/patient days and each clinical outcome in each facility type (all rho < 0.5).

2.3. Factors for Carbapenem Consumption Using a Linear Regression Model

Table 3 shows the results of a linear regression model of factors for hospital carbapenem consumption. Only MDCs were associated with carbapenem consumption in university hospitals (MDC 3 and 6) and university hospital-equivalent community hospitals (MDC 13). In community hospitals and non-DPC hospitals, various MDCs (e.g., MDC 4 and 13), and clinical outcomes including discharge with cure, readmission rate, and length of stay were associated with carbapenem consumption.

3. Discussion

To our best knowledge, this is the first study to reveal the association between carbapenem consumption and major clinical outcomes in various facility types based on DPC database analysis. The large dispersion of carbapenem consumption in community and non-DPC hospitals would indicate concern about inappropriate carbapenem use in these hospitals.
In Japan, large-sized hospitals, such as university hospitals and university hospital-equivalent community hospitals, mainly hospitalize acute and critical illness cases, and transfer them to small or medium-sized hospitals after treatment. Conversely, patients admitted at small- and medium-sized hospitals are transferred to large hospitals when their disease becomes severe. Each prefecture in Japan is classified by medical region and these prefectures provide a medical care system in cooperation [26]. This study revealed no association between carbapenem consumption and clinical outcomes, despite a high median carbapenem consumption in large-sized hospitals compared with the community hospitals, DPC-prepared hospitals, and non-DPC hospitals. AST in large-sized hospitals that have sufficient human resources could facilitate appropriate carbapenem use according to their various inpatient backgrounds [9,27,28,29]. Whereas, carbapenem consumption was associated with the increment of discharge with cure and readmission in community, and non-DPC hospitals. Several studies and guidelines have supported the clinical efficacy of carbapenems [2,30,31]. However, the increment in carbapenem consumption was also associated with the readmission rate. These inconsistent results may be caused by different disease severity and patient comorbidities. The increment of readmission would be caused by disease severity and complicated comorbidities other than infectious diseases, although carbapenems are highly efficacious and could improve patient outcomes. The MDCs and clinical outcomes were extracted as associated factors for carbapenem consumption in community and non-DPC hospitals because patients admitted at small- and medium-sized hospitals, including those that transferred from large-sized hospitals, have various backgrounds.
Our previous DPC database analysis revealed that various MDCs were significantly associated with an increment in carbapenem consumption [32]. The stratification result by facility type in this study revealed a few associated factors in university hospitals and university hospital-equivalent community hospitals. Detecting the specific associated factors in carbapenem consumption would be difficult, considering the similar medical functions and inpatient backgrounds in these hospitals. Meanwhile, respiratory diseases (MDC4) and hematologic diseases (MDC13) were significantly associated with the increment of carbapenem consumption in community hospitals consistent with the previous study [32]. Rhodes et al. revealed the predictors of carbapenem consumption across North American hospitals [33]. The linear mixed-effects model revealed that non-carbapenem consumption, antibiogram publication, and license bed size were associated with carbapenem consumption [33]. Additionally, the rates of carbapenem consumption differed greatly among the hospitals. Our study revealed that inpatient backgrounds affect carbapenem consumption, which reinforces the importance of carbapenem consumption benchmarks according to each hospital’s characteristics.
The burden of carbapenem overuse associated with antibiotic selective pressure would be alarming nationwide, considering the number of community and non-DPC hospitals [12,14]. Various inpatient backgrounds and clinical outcomes in community hospitals were associated with carbapenem consumption. Additionally, the heterogeneity of carbapenem consumption was speculated. Carbapenem overuse and misusage in these hospitals would be concerning. A previous study recommended that institutional guidelines for carbapenem use should focus on four common infectious diseases, such as respiratory, genitourinary, intra-abdominal, and bloodstream, to promote carbapenem stewardship [34]. However, previous investigations revealed that small- to medium-size hospitals had limited resources to promote antimicrobial stewardship [18,35,36]. Increased commitment by policymakers and stakeholders to support community and non-DPC hospitals would be needed using the benchmark of the carbapenem consumption metric.
Several important study limitations should be noted. First, the patient individual background (e.g., comorbidities) and severity indices (e.g., sequential organ failure assessment score) were not available from the DPC database. Moreover, the population of this study included patients with diseases other than infectious diseases. An available database of specific infectious diseases and antimicrobial consumption, including patient and facility data, has been limited in Japan. Second, a metric for antimicrobial consumption other than carbapenems was not analyzed because the DPC database has not disclosed antimicrobial consumption other than carbapenems. Metrics for each antimicrobial categorization akin to the standardized antimicrobial administration ratio can be developed, provided that the MHLW discloses various antimicrobial consumption [37]. Standardized metrics combined with patients’ clinical outcomes will be utilized [38]. The previous multicenter study in Japan reported the correlation between carbapenem use and the rate of carbapenem-resistant Pseudomonas aeruginosa using the Japanese surveillance system [39]. The development of a database for infectious diseases and antimicrobial consumption that is accessible from every Japanese hospital would be needed to evaluate the appropriate antibiotic consumption in each hospital [39,40].

4. Materials and Methods

4.1. Data Sources

This study analyzed data on carbapenem consumption (presented as DDDs per 1000 patient days) of inpatients across 5316 healthcare facilities collected by the MHLW in the fiscal year 2020 [21]. Imipenem, meropenem, doripenem, panipenem, and biapenem injections were approved for consumption in Japan.
The data included clinical outcomes at discharge (rate of cure, remission, stable disease, exacerbation, death, and others), readmission and length of stay, number of beds, and MDCs. MDCs were principal diagnoses (from the International Classification of Diseases 10th Revision (ICD-10)) of inpatients into the following 18 mutually exclusive diagnosis areas: diseases and disorders of the (1) nervous system; (2) eye; (3) ears, nose, mouth, and throat; (4) respiratory system; (5) circulatory system; (6) digestive system, hepatobiliary system, and pancreas; (7) musculoskeletal system; (8) skin and subcutaneous tissue; (9) breast; (10) endocrine, nutritional, and metabolic system; (11) kidney, urinary tract, and male reproductive system; (12) female reproductive system, pregnancy, childbirth, and puerperium; (13) blood and blood-forming organs, and immunological disorders; (14) newborn and other neonates with conditions originating from the perinatal period; (15) pediatric; (16) injuries, burns, poisoning, and the toxic effect of drugs; (17) mental; and (18) others. MDCs were a group of 18 diseases based on the ICD-10, and evaluating the differences in the background of inpatients at each medical institution as a factor is possible using this ratio.

4.2. Statistical Analysis

Hospital characteristics of each facility type were presented as median and interquartile range owing to the non-normal distribution. Carbapenem DDDs/1000 patient days in each facility type were summarized using a boxplot. Multiple comparisons were performed using the Kruskal-Wallis test with Bonferroni correction. Spearman’s rank correlation coefficient was utilized to investigate the possible association between the carbapenem consumption and the major clinical outcomes (discharge with cure, readmission within 4 weeks, and average length of stay) in each facility type.
Then, we performed a multivariable linear regression analysis using a stepwise method for each facility type to identify factors related to carbapenem consumption. We selected clinical outcomes (discharge with cure, readmission within 4 weeks, and average length of stay), the number of hospital beds (per 100 beds increment), and each of the MDCs as covariates.
Multicollinearity was assessed using the Spearman’s rank correlation coefficient and variance inflation factor. All the statistical analyses were two-tailed, with p-values of <0.05 indicating statistical significance. Statistical analyses were performed using the Statistical Package for the Social Sciences version 27.0 (IBM Japan, Tokyo, Japan).
This study required no ethical approval or informed consent because only publicly accessible data on the MHLW homepages were obtained.

5. Conclusions

In conclusion, carbapenem consumption in community and non-DPC hospitals was associated with major clinical outcomes and inpatient characteristics based on national database analysis. Both carbapenem overuse and underuse are alarming for patient clinical outcomes and antimicrobial resistance. Thus, we revealed the model of carbapenem consumption, including patients and hospital characteristics. Further studies are needed to develop uniformly applied metrics to evaluate appropriate antimicrobial consumption across diverse healthcare settings.

Author Contributions

Conceptualization, M.M. and Y.M.; methodology, K.Y. and M.M.; validation, M.M. and Y.M.; formal analysis, K.Y.; investigation, M.M. and K.Y.; resources, M.M. and N.O.; data curation, M.M.; writing—original draft preparation, K.Y. and M.M.; writing—review and editing, M.M. and Y.M.; visualization, K.Y.; supervision, N.O. and Y.M.; project administration, M.M. and N.O. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by JSPS KAKENHI (grant number 20K16090) and the Ministry of Health, Labor, and Welfare (grant number 20HA2003).

Institutional Review Board Statement

This study required no institutional review board approval or informed consent given that only publicly accessible data on government homepages obtained through the internet were used.

Informed Consent Statement

Not applicable.

Data Availability Statement

Publicly available datasets were analyzed in this study. These data can be found here: [https://www.mhlw.go.jp/stf/shingi2/0000196043_00005.html (accessed on 20 April 2022)].

Conflicts of Interest

The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Wilson, A.P.R. Sparing carbapenem usage. J. Antimicrob. Chemother. 2017, 72, 2410–2417. [Google Scholar] [CrossRef] [PubMed]
  2. Solomkin, J.S.; Mazuski, J.E.; Bradley, J.S.; Rodvold, K.A.; Goldstein, E.J.C.; Baron, E.J.; O’Neill, P.J.O.; Chow, A.W.; Dellinger, E.P.; Eachempati, S.R.; et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg. Infect. 2010, 11, 79–109. [Google Scholar] [CrossRef] [PubMed]
  3. Wilson, A.P.R.; Livermore, D.M.; Otter, J.A.; Warren, R.E.; Jenks, P.; Enoch, D.A.; Newsholme, W.; Oppenheim, B.; Leanord, A.; McNulty, C.; et al. Prevention and control of multi-drug-resistant Gram-negative bacteria: Recommendations from a Joint Working Party. J. Hosp. Infect. 2016, 92, S1–S44. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Giske, C.G.; Monnet, D.L.; Cars, O.; Carmeli, Y.; ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob. Agents Chemother. 2008, 52, 813–821. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Ministry of Health, Labour and Welfare Japan Nosocomial Infections Surveillance Annual Open Report. Clinical Laboratory Division 2020. Available online: https://janis.mhlw.go.jp/english/report/open_report/2020/3/1/ken_Open_Report_Eng_202000_clsi2012.pdf (accessed on 14 October 2022).
  6. Oka, K.; Matsumoto, A.; Tetsuka, N.; Morioka, H.; Iguchi, M.; Ishiguro, N.; Nagamori, T.; Takahashi, S.; Saito, N.; Tokuda, K.; et al. Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan. J. Glob. Antimicrob. Resist. 2022, 29, 247–252. [Google Scholar] [CrossRef] [PubMed]
  7. The Government of Japan: National Action Plan on Antimicrobial Resistance (AMR), 2016–2020. Available online: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000120172.html (accessed on 14 October 2022).
  8. Seah, V.X.F.; Ong, R.Y.L.; Lim, A.S.Y.; Chong, C.Y.; Tan, N.W.H.; Thoon, K.C. Impact of a carbapenem antimicrobial stewardship program on patient outcomes. Antimicrob. Agents Chemother. 2017, 61, e00736-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Suzuki, A.; Maeda, M.; Yokoe, T.; Hashiguchi, M.; Togashi, M.; Ishino, K. Impact of the multidisciplinary antimicrobial stewardship team intervention focusing on carbapenem de-escalation: A single-centre and interrupted time series analysis. Int. J. Clin. Pract. 2021, 75, e13693. [Google Scholar] [CrossRef]
  10. Lau, C.L.; Periyasamy, P.; Saud, M.N.; Robert, S.A.; Gan, L.Y.; Chin, S.Y.; Pau, K.B.; Kong, S.H.; Tajurudin, F.W.; Yin, M.K.; et al. Plethora of antibiotics usage and evaluation of carbapenem prescribing pattern in intensive care units: A single-center experience of Malaysian academic hospital. Antibiotics 2022, 11, 1172. [Google Scholar] [CrossRef]
  11. Wells, D.A.; Johnson, A.J.; Lukas, J.G.; Mason, D.; Cleveland, K.O.; Bissell, A.; Hobbs, A.L.V. Criteria Restricting Inappropriate Meropenem Empiricism (CRIME): A quasi-experimental carbapenem restriction pilot at a large academic medical centre. Int. J. Antimicrob. Agents 2022, 60, 106661. [Google Scholar] [CrossRef]
  12. Yamasaki, D.; Tanabe, M.; Muraki, Y.; Kato, G.; Ohmagari, N.; Yagi, T. The first report of Japanese antimicrobial use measured by national database based on health insurance claims data (2011–2013): Comparison with sales data, and trend analysis stratified by antimicrobial category and age group. Infection 2018, 46, 207–214. [Google Scholar] [CrossRef] [PubMed]
  13. Ebisui, A.; Inose, R.; Kusama, Y.; Koizumi, R.; Kawabe, A.; Ishii, S.; Goto, R.; Ishikane, M.; Yagi, T.; Ohmagari, N.; et al. Trends in antipseudomonal agent use based on the 2006 to 2015 sales data in Japan. Biol. Pharm. Bull. 2021, 44, 816–821. [Google Scholar] [CrossRef] [PubMed]
  14. Terahara, F.; Nishiura, H. Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: An ecological study. J. Int. Med. Res. 2019, 47, 4711–4722. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Barlam, T.F.; Cosgrove, S.E.; Abbo, L.M.; MacDougall, C.; Schuetz, A.N.; Septimus, E.J.; Srinivasan, A.; Dellit, T.H.; Falck-Ytter, Y.T.; Fishman, N.O.; et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin. Infect. Dis. 2016, 62, e51–e77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Ministry of Health, Labour and Welfare, Japan: The Fiscal Year 2018 Revision of Reimbursement of Medical Fees. Available online: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000188411.html (accessed on 14 October 2022).
  17. Maeda, M.; Muraki, Y.; Kosaka, T.; Yamada, T.; Aoki, Y.; Kaku, M.; Kawaguchi, T.; Seki, M.; Tanabe, Y.; Fujita, N.; et al. The first nationwide survey of antimicrobial stewardship programs conducted by the Japanese Society of Chemotherapy. J. Infect. Chemother. 2019, 25, 83–88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Maeda, M.; Muraki, Y.; Kosaka, T.; Yamada, T.; Aoki, Y.; Kaku, M.; Seki, M.; Tanabe, Y.; Fujita, N.; Niki, Y.; et al. Impact of health policy on structural requisites for antimicrobial stewardship: A nationwide survey conducted in Japanese hospitals after enforcing the revised reimbursement system for antimicrobial stewardship programs. J. Infect. Chemother. 2021, 27, 1–6. [Google Scholar] [CrossRef]
  19. Matsuda, S.; Fujimori, K.; Kuwabara, K.; Ishikawa, K.B.; Fushimi, K. Diagnosis procedure combination as an infrastructure for the clinical study. Asian Pac. J. Dis. Manag. 2011, 5, 81–87. [Google Scholar] [CrossRef]
  20. Hayashida, K.; Murakami, G.; Matsuda, S.; Fushimi, K. History and profile of diagnosis procedure combination (DPC): Development of a real data collection system for acute inpatient care in Japan. J. Epidemiol. 2021, 31, 1–11. [Google Scholar] [CrossRef]
  21. Ministry of Health, Labour and Welfare Health “Survey on Impact Assessment of DPC Introduction: Summary of Statistics”. Available online: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000049343.html (accessed on 14 October 2022).
  22. World Health Organization Anatomical Therapeutic Chemical (ATC) Classification. Available online: https://www.who.int/tools/atc-ddd-toolkit/atc-classification (accessed on 14 October 2022).
  23. Polk, R.E.; Fox, C.; Mahoney, A.; Letcavage, J.; MacDougall, C. Measurement of adult antibacterial drug use in 130 US hospitals: Comparison of defined daily dose and days of therapy. Clin. Infect. Dis. 2007, 44, 664–670. [Google Scholar] [CrossRef]
  24. Kuster, S.P.; Ruef, C.; Ledergerber, B.; Hintermann, A.; Deplazes, C.; Neuber, L.; Weber, R. Quantitative antibiotic use in hospitals: Comparison of measurements, literature review, and recommendations for a standard of reporting. Infection 2008, 36, 549–559. [Google Scholar] [CrossRef] [Green Version]
  25. Gravatt, L.A.H.; Pakyz, A.L. Challenges in measuring antibiotic consumption. Curr. Infect. Dis. Rep. 2013, 15, 559–563. [Google Scholar] [CrossRef]
  26. Mizuno, K.; Inose, R.; Matsui, Y.; Takata, M.; Yamasaki, D.; Kusama, Y.; Koizumi, R.; Ishikane, M.; Tanabe, M.; Ohge, H.; et al. Search for indexes to evaluate trends in antibiotic use in the sub-prefectural regions using the national database of health insurance claims and specific health checkups of Japan. Antibiotics 2022, 11, 763. [Google Scholar] [CrossRef] [PubMed]
  27. Kagami, K.; Ishiguro, N.; Yamada, T.; Niinuma, Y.; Iwasaki, S.; Taki, K.; Fukumoto, T.; Hayasaka, K.; Nishida, M.; Sugita, J.; et al. Clinical outcomes of intervention for carbapenems and anti-methicillin-resistant Staphylococcus aureus antibiotics by an antimicrobial stewardship team. Am. J. Infect. Control 2021, 49, 1493–1498. [Google Scholar] [CrossRef] [PubMed]
  28. Naito, Y.; Maeda, M.; Nagatomo, Y.; Ugajin, K.; Akima, E.; Tanaka, M.; Tokimatsu, I.; Sasaki, T. Impact of the antimicrobial stewardship team intervention focusing on changes in prescribing trends and the rate of carbapenem-resistant P. aeruginosa. Yakugaku Zasshi 2022, 142, 527–534. [Google Scholar] [CrossRef] [PubMed]
  29. Umemura, T.; Mutoh, Y.; Maeda, M.; Hagihara, M.; Ohta, A.; Mizuno, T.; Kato, H.; Sukawa, M.; Yamada, T.; Ikeda, Y.; et al. Impact of hospital environmental cleaning with a potassium peroxymonosulphate-based environmental disinfectant and antimicrobial stewardship on the reduction of hospital-onset Clostridioides difficile infections. J. Hosp. Infect. 2022, 129, 181–188. [Google Scholar] [CrossRef]
  30. Tamma, P.D.; Aitken, S.L.; Bonomo, R.A.; Mathers, A.J.; van Duin, D.; Clancy, C.J. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin. Infect. Dis. 2022, 74, 2089–2114. [Google Scholar] [CrossRef]
  31. Harris, P.N.A.; Tambyah, P.A.; Lye, D.C.; Mo, Y.; Lee, T.H.; Yilmaz, M.; Alenazi, T.H.; Arabi, Y.; Falcone, M.; Bassetti, M.; et al. MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Effect of Piperacillin-Tazobactam vs. Meropenem on 30-Day Mortality for Patients with E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA 2018, 320, 984–994. [Google Scholar]
  32. Maeda, M.; Muraki, Y.; Anno, Y.; Sawa, A.; Kusama, Y.; Ishikane, M.; Ohmagari, N.; Ohge, H. Development of the predicted and standardized carbapenem usage metric: Analysis of the Japanese Diagnosis Procedure Combination payment system data. J. Infect. Chemother. 2020, 26, 633–635. [Google Scholar] [CrossRef] [Green Version]
  33. Rhodes, N.J.; Wagner, J.L.; Davis, S.L.; Bosso, J.A.; Goff, D.A.; Rybak, M.J.; Scheetz, M.H.; MAD-ID Research Network. Trends in and predictors of carbapenem consumption across North American hospitals: Results from a multicenter survey by the MAD-ID research network. Antimicrob. Agents Chemother. 2019, 63, e00327-19. [Google Scholar] [CrossRef] [Green Version]
  34. Wagner, J.L.; Rhodes, N.J.; Scheetz, M.H.; Bosso, J.A.; Goff, D.A.; Rybak, M.J.; Davis, S.L.; MAD-ID Research Network. Opportunities for antimicrobial stewardship among carbapenem-treated patients in 18 North American hospitals. Int. J. Antimicrob. Agents 2020, 55, 105970. [Google Scholar] [CrossRef]
  35. Maeda, M.; Muraki, Y.; Kosaka, T.; Yamada, T.; Aoki, Y.; Kaku, M.; Seki, M.; Tanabe, Y.; Fujita, N.; Niki, Y.; et al. Essential human resources for antimicrobial stewardship teams in Japan: Estimates from a nationwide survey conducted by the Japanese Society of Chemotherapy. J. Infect. Chemother. 2019, 25, 653–656. [Google Scholar] [CrossRef] [Green Version]
  36. Maeda, M.; Miyake, T.; Inose, R.; Ueda, S.; Matsugi, K.-I.; Muraki, Y.; Kitahara, T. Bibliometric analysis of pharmacist’s research on antimicrobial stewardship in Japan: An interrupted time series analysis on the implementation of the certification system for infection control pharmacists. J. Pharm. Health Care Sci. 2021, 7, 38. [Google Scholar] [CrossRef]
  37. van Santen, K.L.; Edwards, J.R.; Webb, A.K.; Pollack, L.A.; O’Leary, E.; Neuhauser, M.M.; Srinivasan, A.; Pollock, D.A. The standardized antimicrobial administration ratio: A new metric for measuring and comparing antibiotic use. Clin. Infect. Dis. 2018, 67, 179–185. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Ibrahim, O.M.; Polk, R.E. Antimicrobial use metrics and benchmarking to improve stewardship outcomes: Methodology, opportunities, and challenges. Infect. Dis. Clin. N. Am. 2014, 28, 195–214. [Google Scholar] [CrossRef] [PubMed]
  39. Kagami, K.; Ishiguro, N.; Iwasaki, S.; Usami, T.; Fukumoto, T.; Hayasaka, K.; Oyamada, R.; Watanabe, T.; Nakakubo, S.; Niinuma, Y.; et al. Correlation between antibiotic use and antibiotic resistance: A multicenter study using the Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system in Hokkaido, Japan. Am. J. Infect. Control, 2022; in press. [Google Scholar] [CrossRef]
  40. Endo, A.; Asai, Y.; Tajima, T.; Endo, M.; Akiyama, T.; Matsunaga, N.; Ishioka, H.; Tsuzuki, S.; Ohmagari, N. Temporal trends in microbial detection during the COVID-19 pandemic: Analysis of the Japan surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) database. J. Infect. Chemother. 2022, 29, 98–101. [Google Scholar] [CrossRef] [PubMed]
Antibiotics 11 01807 g001 550
Figure 1. Study flow diagram showing the stratification and selection of patients in the Diagnosis Procedure Combination database by the Ministry of Health and Welfare in the fiscal year 2020.
Figure 1. Study flow diagram showing the stratification and selection of patients in the Diagnosis Procedure Combination database by the Ministry of Health and Welfare in the fiscal year 2020.
Antibiotics 11 01807 g001
Antibiotics 11 01807 g002 550
Figure 2. Median carbapenem consumption stratified by facility type. The outliners were plotted on the box plot as a small circle and a star.
Figure 2. Median carbapenem consumption stratified by facility type. The outliners were plotted on the box plot as a small circle and a star.
Antibiotics 11 01807 g002
Table
Table 1. Characteristics of hospitals stratified by facility type.
Table 1. Characteristics of hospitals stratified by facility type.
University
Hospitals
(N = 82)		University
Hospital-Equivalent
Community
Hospitals
(N = 156)		Community
Hospitals
(N = 1510)		DPC-Prepared Hospitals
(N = 242)		Non-DPC
Hospitals
(N = 2918)
Number of licensed beds821 (643–968)578 (477–675)260 (180–367)148 (102–199)107 (64–168)
Outcome at discharge
 Cure (%)77.17 (71.97–83.85)81.24 (77.09–85.71)82.66 (76.84–87.04)81.80 (72.69–87.62)76.83 (62.61–86.21)
 Remission (%)0.23 (0.066–0.406)0.13 (0.03–0.56)0.06 (0–0.31)0.03 (0–0.29)0 (0–0.66)
 Stable disease (%)12.54 (5.68–18.03)8.08 (3.58–11.60)6.15 (2.79–10.89)6.37 (2.67–12.28)7.05 (2.45–13.55)
 Exacerbation (%)0.063 (0.024–0.13)0.03 (0.01–0.13)0.12 (0.03–0.32)0.40 (0.11–0.84)0.63 (0–1.76)
 Death (%)1.43 (1.08–1.795)2.57 (2.04–3.19)3.62 (2.51–5.12)4.41 (2.56–6.75)6.87 (2.93–12.22)
 Others (%)8.54 (5.68–10.54)7.11 (5.44–8.98)5.22 (2.74–7.96)2.27 (0.43–6.22)0.65 (0–4.37)
Readmission within 4 weeks (%)14.51 (12.68–16.55)12.47 (10.55–14.69)9.93 (7.31–12.76)8.04 (4.50–12.01)5.73 (3.14–9.75)
Average length of stay (day)12.14 (11.60–12.98)11.39 (10.81–12.14)12.15 (10.71–13.54)12.78 (10.49–15.30)14.46 (10.93–18.22)
Data were presented as median (interquartile range).
Table
Table 2. Correlation analysis results of carbapenem consumption stratified by facility type, cure, readmission within 4 weeks, and average length of stay.
Table 2. Correlation analysis results of carbapenem consumption stratified by facility type, cure, readmission within 4 weeks, and average length of stay.
Spearman’s Correlation Coefficient (ρ)p-Value
University hospitals
 Cure rate−0.0680.541
 Rate of readmission within 4 weeks−0.3110.004
 Average length of stay−0.0010.993
University hospital-equivalent community hospitals
 Cure rate−0.1110.167
 Rate of readmission within 4 weeks0.130.098
 Average length of stay0.0210.792
Community hospitals
 Cure rate−0.0560.03
 Rate of readmission within 4 weeks0.342<0.001
 Average length of stay0.0070.794
DPC-prepared hospitals
 Cure rate−0.1130.081
 Rate of readmission within 4 weeks0.483<0.001
 Average length of stay−0.0140.829
Non-DPC hospitals
 Cure rate−0.098<0.001
 Rate of readmission within 4 weeks0.265<0.001
 Average length of stay0.0050.811
DPC, diagnosis procedure combination.
Table
Table 3. Multivariable linear regression models of associated factors of carbapenem consumption by facility type.
Table 3. Multivariable linear regression models of associated factors of carbapenem consumption by facility type.
FactorsPartial Regression Coefficient
(95% Confidence Interval)		p-Value
Model 1 a (university hospitals)
 MDC 03 (ear, nose, mouth, and throat)106.643(5.581–207.705)0.039
 MDC 16 (injuries, burns, poisoning, and toxic effect of drugs)133.498(22.872–244.124)0.019
 Constant term9.683(3.800–15.565)0.002
Model 2 b (university hospital-equivalent community hospitals)
 MDC 13 (blood and immunological disorders)92.997(32.170–153.824)0.003
 Constant term13.930(11.352–16.508)0.000
Model 3 c (community hospitals)
 Cure rate9.955(5.687–14.222)0.000
 Rate of readmission within 4 weeks15.361(5.878–24.843)0.002
 Average length of stay0.176(0.016–0.335)0.031
 Licensed bed size *1.188(0.931–1.445)0.000
 MDC 01 (nervous system)−4.911(−8.368 to −1.454)0.005
 MDC 04 (respiratory system)8.127(2.221–14.034)0.007
 MDC 07 (musculoskeletal system)−12.784(−17.522 to −8.046)0.000
 MDC 09 (breast)−16.717(−27.749 to −5.685)0.003
 MDC 10 (endocrine, nutritional, and metabolic system)−19.321(−31.693 to −6.950)0.002
 MDC 13 (blood and immunological disorders)62.499(48.049–76.950)0.000
 MDC 14 (newborn)−24.892(−34.774 to −15.009)0.000
 MDC 16 (injuries, burns, poisoning, and toxic effect of drugs)−7.841(−13.039 to −2.642)0.003
 MDC 17 (mental disorders)−169.432(−256.636 to −82.227)0.000
Model 4 d (DPC-prepared hospitals)
 Cure rate12.344(4.946–19.742)0.001
 Rate of readmission within 4 weeks31.157(14.330–47.984)0.000
 MDC 02 (eye)−10.099(−19.786 to −0.413)0.041
 MDC 04 (respiratory system)24.198(14.422–33.975)0.000
 MDC 11 (kidney, urinary tract, and male reproductive system)13.260(5.408–21.112)0.001
 MDC 15 (pediatric)−178.586(−302.983 to−54.190)0.005
 MDC 16 (injuries, burns, poisoning, and toxic effect of drugs)−9.409(−16.880 to −1.938)0.014
Model 5 e (non-DPC hospitals)
 Cure rate1.890(0.283–3.498)0.021
 Rate of readmission within 4 weeks19.484(14.966–24.002)0.000
 MDC 04 (respiratory system)16.127(13.091–19.162)0.000
 MDC 05 (circulatory system)4.174(1.417–6.931)0.003
 MDC 06 (digestive and hepatobiliary system, and pancreas)4.790(3.475–6.104)0.000
 MDC 11 (kidney, urinary tract, and male reproductive system)7.595(5.144–10.047)0.000
 MDC 13 (blood and immunological disorders)26.154(17.447–34.861)0.000
DPC, diagnosis procedure combination; MDC, major diagnostic. MDC No. (diagnosis areas). * Indicates increments of 100 beds. Stepwise method: a R2 = 0.109, Durbin-Watson = 1.690; b R2 = 0.056, Durbin-Watson = 1.993; c R2 = 0.250, Durbin-Watson = 1.892; d R2 = 0.265, Durbin-Watson = 2.098; e R2 = 0.130, Durbin-Watson = 1.980.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Yamaguchi, K.; Maeda, M.; Ohmagari, N.; Muraki, Y. Association between Carbapenem Consumption and Clinical Outcomes in an In-Hospital Setting: Analysis of a Japanese Nationwide Administrative Database in 2020. Antibiotics 2022, 11, 1807. https://doi.org/10.3390/antibiotics11121807

AMA Style

Yamaguchi K, Maeda M, Ohmagari N, Muraki Y. Association between Carbapenem Consumption and Clinical Outcomes in an In-Hospital Setting: Analysis of a Japanese Nationwide Administrative Database in 2020. Antibiotics. 2022; 11(12):1807. https://doi.org/10.3390/antibiotics11121807

Chicago/Turabian Style

Yamaguchi, Kozue, Masayuki Maeda, Norio Ohmagari, and Yuichi Muraki. 2022. "Association between Carbapenem Consumption and Clinical Outcomes in an In-Hospital Setting: Analysis of a Japanese Nationwide Administrative Database in 2020" Antibiotics 11, no. 12: 1807. https://doi.org/10.3390/antibiotics11121807

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop